STOCK TITAN

Marker Therapeutics (MRKR) Stock News, Apr-Dec 2022

MRKR NASDAQ

Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.

Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.

Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) announced a Common Stock Purchase Agreement with Lincoln Park Capital Fund for up to $25 million. This agreement allows Marker to sell shares at its discretion over a 24-month period, subject to the effectiveness of a registration statement with the SEC. The proceeds will support the Phase 2 ARTEMIS trial of its lead candidate, MT-401, and other clinical programs. CEO Peter Hoang emphasized the importance of this deal for flexible capital access post-restructuring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
-
Rhea-AI Summary

Marker Therapeutics, Inc. (Nasdaq: MRKR) announced FDA clearance for its Investigational New Drug (IND) application for MT-601, a T cell product targeting six antigens for patients with advanced pancreatic cancer. The IND approval marks a significant milestone as the company prepares to initiate a Phase 1 clinical trial in 2023. The new manufacturing process for MT-601 allows production in 9 days with a 90% reduction in interventions, improving the final T cell product. The clinical trial follows encouraging results from the Phase 1 TACTOPS study conducted at Baylor College of Medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
-
Rhea-AI Summary

Marker Therapeutics, Inc. (Nasdaq: MRKR) has been awarded a $2 million U.S. FDA Orphan Products Grant for its Phase 2 ARTEMIS trial of MT-401, targeting post-transplant AML patients. The company has successfully treated six patients using a new T cell manufacturing process, which enhances potency against tumor antigens. Financial results for Q3 2022 show a net loss of $6.9 million, an improvement from $12.4 million the previous year. Cash and equivalents stand at $18.1 million, with R&D expenses rising to $7.3 million. Marker aims to initiate further trials in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
Rhea-AI Summary

Marker Therapeutics has received a $2 million grant from the FDA's Orphan Products Grants program to support its Phase 2 ARTEMIS trial of the multi-antigen targeted T cell therapy, MT-401, in patients with post-transplant acute myeloid leukemia (AML). This grant will fund the evaluation of MT-401 in patients with minimal residual disease after stem cell transplant. The trial aims to assess relapse-free survival and treatment efficacy, with promising initial results suggesting potential benefits for patients facing limited treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.12%
Tags
-
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced that its President and CEO, Peter L. Hoang, will participate in a panel discussion titled, “CAR-T and Beyond: What Are the Next Generation Cell Therapies?” at the Cantor Fitzgerald Cell and Genetic Medicines Conference in New York on September 15, 2022 at 9:20 a.m. ET. This participation highlights the company’s focus on developing innovative T cell-based immunotherapies for treating hematological malignancies and solid tumors, showcasing their commitment to advancing cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.50%
Tags
conferences
-
Rhea-AI Summary

Marker Therapeutics (MRKR) reported its Q2 2022 financial results and corporate updates, highlighting progress in its clinical programs for AML and lymphoma. The company received an $8 million upfront payment from Wilson Wolf, aiding its efforts. MT-401, a treatment for AML, continues to show promise with recent patient results. Additionally, the FDA cleared IND applications for MT-601 targeting lymphoma and pancreatic cancer. However, the company implemented a restructuring plan, reducing its workforce by 23.5% to conserve capital. As of June 30, 2022, cash reserves stood at $25.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.24%
Tags
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) has received FDA clearance for its IND application of MT-601, a novel T cell therapy targeting six tumor-associated antigens. The upcoming Phase 1 trial will focus on patients with relapsed/refractory non-Hodgkin lymphoma who have failed anti-CD19 CAR T therapies. The therapy aims to offer significant advantages, including enhanced durability and reduced severe toxicities compared to traditional CAR-T therapies. The trial highlights a manufacturing process enabling a higher cell dose, which could accelerate treatment timelines and improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
63.64%
Tags
-
Rhea-AI Summary

Marker Therapeutics, Inc. (MRKR) provided a corporate update and Q1 2022 financial results. The company anticipates topline data from its Phase 2 AML trial's Group 2 in Q2 2022. Initial results from the trial showed MRD elimination in one patient. Marker plans to file INDs for its second T cell therapy candidate, MT-601, in lymphoma and pancreatic cancer by the end of 2022, with trials to begin in 2023. As of March 31, 2022, cash reserves were $28.8 million, while R&D expenses rose to $7.0 million, and net loss increased to $9.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.90%
Tags
-
Rhea-AI Summary

Marker Therapeutics, Inc. (Nasdaq: MRKR) announced the presentation of four posters on its Multi-Tumor-Associated Antigen (MultiTAA)-specific T cell therapies at the 2022 ISCT Annual Meeting in San Francisco from May 4-7, 2022. CEO Peter L. Hoang highlighted improvements in manufacturing processes leading to faster production and enhanced potency, particularly for MT-401 in Phase 2 trials for post-transplant AML. The posters will cover topics including the clinical results from the Phase 2 AML trial and advances in T cell manufacturing technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.00%
Tags
conferences
Rhea-AI Summary

Marker Therapeutics (MRKR) announced a services agreement with Wilson Wolf Manufacturing, featuring an $8 million upfront payment and a potential additional $1 million. This partnership highlights Marker’s expertise in cell therapy manufacturing, allowing it to maintain control and reduce costs. CEO Peter Hoang emphasized the benefits of having in-house production capabilities. The deal is expected to enhance Marker’s operations, particularly in treating hematological and solid tumors, while showcasing Wilson Wolf's confidence in Marker’s technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.30%
Tags
none

FAQ

What is the current stock price of Marker Therapeutics (MRKR)?

Marker Therapeutics (MRKR) last closed at $1.09.

What is the market cap of Marker Therapeutics (MRKR)?

The market cap of Marker Therapeutics (MRKR) is approximately $18.2M.